PapersPMID:35936217
Clinical Evidence of Acetyl-L-Carnitine Efficacy in the Treatment of Acute Ischemic Stroke: A Pilot Clinical Trial.
- findings
- 3
- compound
- 1
- endpoints
- 3
- Study, every finding
- RCT · 3 days
- Dose studied, every finding
- 1000 mg oral ALC three times per day for three consecutive days (nine doses); nasogastric tube if dysphagia
What moved
How to read these marks →“After three days of the treatment protocol, also the serum levels of TNF- α, IL-6, and ICAM-1, as proinflammatory cytokines, decreased more in the ALC group than in the placebo group (p value = 0.04, 0.02, and 0.03, respectively).”
- Population
- Adults with first-ever acute ischaemic stroke, onset under 24 hours, not candidates for reperfusion therapy, all receiving standard care; change over the 3-day treatment
- Population
- Adults with first-ever acute ischaemic stroke, onset under 24 hours, not candidates for reperfusion therapy, all receiving standard care; change over the 3-day treatment
“Based on the results, 72 hours after the drug administration in the cases receiving ALC, serum levels of TAC, SOD, and GPx, as antioxidants biomarkers, were significantly higher than those in the placebo group (p value = 0.01, 0.02, and 0.01, respectively).”
- Population
- Adults with first-ever acute ischaemic stroke, onset under 24 hours, not candidates for reperfusion therapy, all receiving standard care; measured 72 hours after the first dose
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- patients with first-ever acute ischemic stroke, symptom onset under 24 hours, not candidates for thrombolytic therapy or mechanical thrombectomy
- Participants
- 69
- Comparator
- placebo
- Duration
- 3 days
- Endpoints measured
- 23